Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OMass Therapeutics raises $310M in Series C led by Bain Capital Life Sciences, Forbion, and Novo Holdings to advance its MC2 receptor antagonist into phase 2 development.
Amount Raised
$310 Million
Round Type
Series C
United StatesBiotechnologyInvestors
Description
OMass Therapeutics announced a $310 million Series C funding round, marking the second-largest European biotech raise of 2026. The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings, with participation from Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, and existing backers including GV (Alphabet's VC arm), Syncona, Sanofi Ventures, the British Business Bank, and the University of Oxford. The company plans to use proceeds to advance its lead candidate OMS1620 through phase 2 trials in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. CEO Ros Deegan described the financing as a 'fantastic milestone' on the journey to establish 'Britain's Big Biotech.'
Fundz sees it the moment OMass raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
OMass raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.